Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
Sonia Tadjalli Oskouei, PharmD, BCMAS
Advertisement
Articles by Sonia Tadjalli Oskouei, PharmD, BCMAS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5